Abaloparatide
FDA ApprovedAlso known as: Tymlos, BA058, PTHrP analog
Bone & MetabolicLast reviewed: April 28, 2026
A synthetic analog of parathyroid hormone-related protein (PTHrP) FDA-approved for osteoporosis. Similar to teriparatide but with a potentially more favorable bone-building to bone-resorbing ratio and lower hypercalcemia risk.
Mechanism of Action
Selectively activates the RG conformation of the PTH1 receptor, producing a more transient signaling response than teriparatide. This results in robust bone formation with less bone resorption and less calcium mobilization from bone.
Common Uses
- Postmenopausal osteoporosis
- Fracture risk reduction
- Bone density improvement
Known Risks
- Osteosarcoma risk (boxed warning — animal studies)
- Dizziness
- Nausea
- Tachycardia
- Injection site reactions
- Limited to 2 years of use
Regulatory Status
FDA-approved as Tymlos (2017) for treatment of postmenopausal women with osteoporosis at high fracture risk. Limited to 2 years. Pen injector for daily self-administration.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
80 mcg
Frequency
Once daily
Cycle Length
Up to 24 months
Self-administered via pen injector in the periumbilical region. Refrigerate pen. Follow with anti-resorptive therapy after completing course.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.